<DOC>
	<DOC>NCT02353897</DOC>
	<brief_summary>This study aims to look at patient and physician satisfaction of long term Glabellar lines (GL) treatment with Dysport in a real life setting. It will also allow better understanding of what patients expect from the treatment, and the injection practices used by doctors.</brief_summary>
	<brief_title>Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®</brief_title>
	<detailed_description />
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<criteria>Adult patient with moderate to severe GL naïve of any type of aesthetic treatment/procedure (invasive and noninvasive) for GL who provided written informed consent to take part. Patient who has prior to and independent of the study decided to undergo long term treatment of GL only (at least three cycles). Patient able to comply with the protocol (completion of web questionnaires). Patient whom physician intended to treat with Dysport independent of participation in the study. Patient already included in this study. Participation in an interventional trial within 30 days prior to study entry. Patient who is at risk in terms of precautions, warnings, and contraindication (follow local Summary of Product Characteristics (SmPC) of Dysport). Female patient who is pregnant, nursing or planning a pregnancy during the study. Hypersensitivity to Dysport® or to its excipients. Presence of infection at the proposed injection sites. Presence of myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>